Clinical Trial Update: Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating KRT-232 or TL-895 in JAK inhibitor–treated myelofibrosis patients remains in status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• KRT-232

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Phase 2 | Status: UNKNOWN